
M K Proteins Sees Revision in Market Evaluation Amid Mixed Financial Signals
2025-12-03 11:08:35M K Proteins, a microcap player in the edible oil sector, has experienced a revision in its market evaluation metrics, reflecting nuanced shifts across key financial and technical parameters. This adjustment comes amid ongoing challenges in the company’s financial performance and stock price trends, underscoring the complexities faced by investors in this segment.
Read MoreWhy is M K Proteins falling/rising?
2025-11-26 01:26:29Recent Price Movement and Market Context The stock has been on a downward trajectory, losing 3.83% over the past four consecutive days. Despite outperforming its sector by 2.54% today, M K Proteins remains under pressure, trading below all key moving averages including the 5-day, 20-day, 50-day, 100-day, and 200-day marks. This technical weakness signals a lack of short- to medium-term buying interest. The broader solvent extraction sector has also declined by 4.2%, indicating sector-wide headwinds that are compounding the stock’s difficulties. Investor participation appears to be waning, with delivery volumes on 24 Nov falling by 14.27% compared to the five-day average. This reduction in trading activity suggests diminished enthusiasm among shareholders and potential ...
Read MoreHow has been the historical performance of M K Proteins?
2025-11-24 23:24:00Revenue and Profit Trends Examining net sales, M K Proteins experienced notable volatility. Sales peaked in fiscal years 2021 and 2023, reaching over ₹310 crores, while the lowest recorded sales were in 2019 at approximately ₹156 crores. The latest fiscal year ended March 2025 saw net sales at ₹267.71 crores, reflecting a moderate recovery from the previous year’s ₹245.57 crores but still below the highs of 2021 and 2023. Operating profit before depreciation and interest (PBDIT) excluding other income showed a similar pattern, with a peak around ₹17 crores in 2023 and a decline to ₹12.43 crores in 2025. The operating profit margin correspondingly decreased to 4.64% in 2025 from a high of 6.77% in 2024, indicating margin pressures despite revenue growth. Profit after ta...
Read MoreIs M K Proteins overvalued or undervalued?
2025-11-20 08:08:27As of 19 November 2025, the valuation grade for M K Proteins has moved from attractive to very attractive, indicating a positive shift in its perceived value. The company is currently assessed as undervalued. Key ratios include a PE ratio of 28.91, an EV to EBITDA of 18.57, and a ROCE of 17.66%. In comparison to its peers, M K Proteins has a significantly lower PE ratio than Manorama Industries, which stands at 45.44, and a more favorable EV to EBITDA ratio than CIAN Agro, which is at 16.34. Despite recent underperformance, with a year-to-date return of -20.34% compared to the Sensex's 9.02%, the strong valuation metrics suggest that M K Proteins presents a compelling investment opportunity....
Read MoreHow has been the historical performance of M K Proteins?
2025-11-17 23:21:28Answer: The historical performance of M K Proteins shows a fluctuating trend in net sales and profitability over the years, with recent figures indicating a decline in sales and profit margins. Breakdown: M K Proteins reported net sales of 267.71 Cr in March 2025, which is an increase from 245.57 Cr in March 2024 but a decrease from 314.86 Cr in March 2023. The total operating income followed a similar pattern, reaching 267.71 Cr in March 2025, up from 245.57 Cr in the previous year but down from 314.86 Cr in March 2023. The total expenditure, excluding depreciation, was 255.28 Cr in March 2025, an increase from 228.95 Cr in March 2024, while the operating profit (PBDIT) decreased to 12.91 Cr from 17.07 Cr in the prior year. Profit before tax also saw a decline to 11.45 Cr in March 2025 from 15.47 Cr in March 2024, leading to a profit after tax of 8.40 Cr, down from 11.21 Cr. The company's total liabilitie...
Read MoreHow has been the historical performance of M K Proteins?
2025-11-15 00:20:04Answer: The historical performance of M K Proteins shows a fluctuating trend in key financial metrics over the years. Breakdown: M K Proteins reported net sales of 267.71 Cr in Mar'25, an increase from 245.57 Cr in Mar'24, but a decline from 314.86 Cr in Mar'23. The total operating income followed a similar pattern, reaching 267.71 Cr in Mar'25, up from 245.57 Cr in the previous year but down from 314.86 Cr in Mar'23. Total expenditure, excluding depreciation, was 255.28 Cr in Mar'25, which was higher than 228.95 Cr in Mar'24 but lower than 297.82 Cr in Mar'23. The operating profit (PBDIT) for Mar'25 was 12.91 Cr, a decrease from 17.07 Cr in Mar'24 and 17.10 Cr in Mar'23. Profit before tax also decreased to 11.45 Cr in Mar'25 from 15.47 Cr in Mar'24. Profit after tax was 8.40 Cr in Mar'25, down from 11.21 Cr in Mar'24. The company's total assets increased to 130.23 Cr in Mar'25 from 95.87 Cr in Mar'24, whi...
Read More
M K Proteins Ltd Surges 1.50% Today, Marking Three Consecutive Days of Gains at 5.72%
2025-11-12 09:41:53M K Proteins Ltd, a microcap in the edible oil sector, is experiencing notable buying activity, marking three consecutive days of gains. Despite a recent uptick, the stock has declined over the past month and year, contrasting with the broader market's performance. The sector's volatility may be influencing investor interest.
Read MoreCompliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
14-Jan-2026 | Source : BSEPursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulation 2018 please find attached herewith copy of Certificate issued by M/s Big Share Services Private Limited for the Quarter ended 31st December 2025.
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
14-Jan-2026 | Source : BSEPursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulation 2018 please find attached herewith copy of Certificate issued by M/s Big Share Services Private Limited for the Quarter ended 31st December 2025.
Closure of Trading Window
29-Dec-2025 | Source : BSETrading Window for transactions in Shares of the Company for all the Employees Directors Key Managerial Personnel Promoters designated persons and their immediate relatives or any other insider shall remain closed from Thursday 1st January 2026 till end of 48 hours after the declaration of Un-Audited Financial Results of the Company for the Quarter ended 31st December 2025.
Corporate Actions
No Upcoming Board Meetings
No Dividend history available
M K Proteins Ltd has announced 1:10 stock split, ex-date: 10 Nov 23
M K Proteins Ltd has announced 2:1 bonus issue, ex-date: 15 Mar 24
No Rights history available